A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma.

Trial Profile

A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Daporinad (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors TopoTarget; TopoTarget Switzerland
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Nov 2012 Actual end date Mar 2009 added as reported by ClinicalTrials.gov.
    • 12 Mar 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top